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This is the first in a series of four articles
that highlight the changing nature of global
health institutions.
The Global Health System: A
Time of Transition
The global health system that evolved
through the latter half of the 20
th century
achieved extraordinary success in control-
ling infectious diseases and reducing child
mortality. Life expectancy in low- and
middle-income countries increased at a
rate of about 5 years every decade for the
past 40 years [1]. Today, however, that
system is in a state of profound transition.
The need has rarely been greater to
rethink how we endeavor to meet global
health needs.
We present here a series of four papers
on one dimension of the global health
transition: its changing institutional ar-
rangements. We define institutional ar-
rangements broadly to include both the
actors (individuals and/or organizations)
that exert influence in global health and
the norms and expectations that govern
the relationships among them (see Box 1
for definitions of the terms used in this
article).
The traditional actors on the global
health stage—most notably national
health ministries and the World Health
Organization (WHO)—are now being
joined (and sometimes challenged) by an
ever-greater variety of civil society and
nongovernmental organizations, private
firms, and private philanthropists. In
addition, there is an ever-growing pres-
ence in the global health policy arena of
low- and middle-income countries, such as
Kenya, Mexico, Brazil, China, India,
Thailand, and South Africa.
Also changing are the relationships
among those old and new actors—the
norms, expectations, and formal and infor-
mal rules that order their interactions. New
‘‘partnerships’’ such as WHO’s Roll Back
Malaria Partnership (RBM), Stop TB, the
Global Alliance for Vaccines and Immuni-
zation (GAVI), the Global Fund to Fight
AIDS, Tuberculosis and Malaria
(GFATM), and many others have come to
exist alongside and somewhat independent-
ly oftraditional intergovernmentalarrange-
ments between sovereign states and UN
bodies (see Figures 1 and 2 for an
illustration of the underlying governance
principles). These partnerships have been
emphasized—not least by WHO itself—as
the mostpromisingformofcollectiveaction
in a globalizing world [2]. Large increases
in international support for the newer
institutions has led to relative and, in some
cases, absolute declines in the financial
importance of traditional actors [3].
The rise of multiple new actors in the
system creates challenges for coordination
but, more fundamentally, raises tightly
linked questions about the roles various
organizations should play, the rules by
which they play, and who sets those rules.
Actors may exercise power within the
constraints of international institutions in
hopes of achieving benefits and shared
objectives [4]. Such a calculus helps to
explain why actors are willing to fund
multilateral initiatives such as WHO,
GFATM, RBM, and Stop TB, despite
the fact that doing so entails relinquishing
considerable control over what is done
with their resources. On the other hand,
powerful and financially independent ac-
tors, such as national governments, may
elect to use their resources to influence the
outcomes from multilateral initiatives or
create bilateral ones. The lack of a clear
set of rules that constrain distortion of
priorities by powerful actors can threaten
less powerful ones. As a case in point,
despite widespread support for its over-
arching goals, there is considerable discus-
sion, in some cases even unease and some
tension, around the prominent role played
by the Bill & Melinda Gates Foundation,
whose spending on global health was
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Finally, this period of transition in
actors and relationships comes at a time
when the very nature of the challenges
faced by health systems is itself being
transformed. The success of child survival
efforts has meant that noncommunicable
diseases, including cardiovascular disease,
cancer, diabetes, and neuropsychiatric
disease, are growing in prevalence along-
side the continuing threats of communica-
ble diseases [9–11]. The globalizing econ-
omy poses a new set of health challenges
as the rules that govern trade in goods,
services, and investment reach more
deeply into national regulatory and health
systems than have previous trade arrange-
ments [12,13]. Finally, changes in climate
and other environmental variables are
likely to create unexpected and unpredict-
able health threats, both as a direct result
of changing environments for disease
vectors and as an indirect result of impacts
on water and food security, extreme
events, and increased migration [14,15].
The melee resulting from these inter-
acting transitions has produced some
extraordinary success stories, such as the
drive that dramatically increased access to
lifesaving antiretroviral therapy for people
living with HIV/AIDS, unprecedented
access to insecticide-treated bednets for
malaria, and enhanced access to anti-TB
drugs in the developing world within a
span of a few short years. But there is also
mounting concern that the increasingly
complex nature of the evolving global
health system leaves unexploited signifi-
cant opportunities for improving global
health, results in duplication and waste of
scarce health resources, and carries high
transaction costs. The ongoing global
financial crisis makes the efficient and
effective performance of the global health
system all the more pressing.
Many have expressed doubts that to-
day’s global health system is remotely
adequate for meeting the emerging chal-
lenges of the 21
st century [21–24]. A
groundswell of opinion [25–35] suggests
that new thinking is needed on whether or
how practical reform of the present
complex global health system can improve
its ability to deal with such key issues as:
N Setting global health agendas in ways
that not only build upon the enthusi-
asm of particular actors, but also
improve the coordination necessary
to avoid waste, inefficiency, and turf
wars.
N Ensuring a stable and adequate flow of
resources for global health, while
safeguarding the political mobilization
that generates issue-specific funding.
How can the global burden of financ-
ing be equitably shared, and who
decides? How should resources be
allocated to meet the greatest health
risks, particularly those that lack vocal
advocates?
N Ensuring sufficient long-term invest-
ment in health research and develop-
ment (R&D). Who should contribute,
and who should pay? How can the
dynamism and capacity of both public
and private sectors from North and
South be harnessed, without compro-
mising the public sector’s regulatory
responsibilities?
Box 1. Defining the Global Health System
We understand global health needs to include disease prevention, quality care,
equitable access, and the provision of health security for all people [16–18]. We
define the global health system as the constellation of actors (individuals and/or
organizations) ‘‘whose primary purpose is to promote, restore or maintain health’’
[19], and ‘‘the persistent and connected sets of rules (formal or informal), that
prescribe behavioral roles, constrain activity, and shape expectations’’ [20] among
them. Such actors may operate at the community, national, or global levels, and
may include governmental, intergovernmental, private for-profit, and/or not-for-
profit entities.
Figure 1. UN-type international health governance. Based on the principles of the UN system, member countries are represented in the World
Health Assembly (WHA), which functions as the central governing body. The WHA appoints the director general, oversees all major organizational
decision making and approves the program budget.
doi:10.1371/journal.pmed.1000183.g001
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and evaluation and judging best prac-
tices—how can policy agreement be
achieved when actors bring contested
views of the facts to the table?
N Learning lessons from the enormous
variance in effectiveness and costs of
various national and international
health systems, from R&D to the
delivery and monitoring and evaluation
(M&E) of interventions in the field, to
create improvements everywhere.
Roadmap of the Series
In this series we undertook a study of the
role of institutions in the global health
system. The aims of the study were
threefold: first, to advance current under-
standing of the interplay of actors in the
system;second, toevaluate itsperformance;
and third, to identify opportunities for
improvement. The project was part of a
larger program led by Harvard University’s
John F. Kennedy School of Government to
advance thinking on the challenges of
linking research knowledge with timely
and effective action in an increasingly
globalized and diverse world [36,37]. It
drew together theoretical literature on
global governance that has emerged from
the field of international relations over the
last half-century [20,38,39]; on empirical
analysis of institutional design and perfor-
mance in other sectors that, similar to
public health, seek to mobilize scientific
knowledge as a global public good (e.g.,
agriculture and environmental protection
[40–42]); and on the engagement of several
of the authors of this paper in contempo-
rary policy debates on ways to improve the
institutions that promote global health
[43,44].
We focused on three central questions
regarding the global health system: (1)
What functions must an effective global
health system accomplish? (2) What kind
of arrangements can better govern the
growing and diverse set of actors in the
system to ensure that those functions are
performed? (3) What lessons can be
extracted from analysis of historical expe-
rience with malaria to inform future efforts
to address them and the coming wave of
new health challenges? To illuminate these
questions, we built a series of case studies,
workshops, and synthesis efforts, the
results of which are reported in more
detail elsewhere (http://www.cid.harvard.
edu/sustsci/events/workshops/08institutions/
index.html).
In the papers presented in this series we
summarize representative results from our
work for one key actor in, and one key
function of, the global health system.
Thus, the second article in the series, by
Frenk [45], reflects on the essential
characteristics of functioning national
health systems, which are the anchoring
institutions of the global health system.
The continued crucial importance of
national health systems as connectors of
research and development with popula-
tions, and as guarantors of the successful
and sustained delivery of health interven-
tions to people and populations, is often
overlooked in enthusiastic discussions of
new approaches to the architecture of
global health. Indeed, the biggest chal-
lenge facing global health today is to
reconcile the ongoing global-level trans-
formation with the need to further
strengthen and support national-level
health systems.
The third article, by Keusch et al. [46],
examines how the global health system has
evolved to better integrate the research,
development, and delivery of health inter-
ventions—a core function of the system.
We chose the global response to malaria as
a good case study because of the long
history of global efforts to combat the
disease, multiple attempts at institution
building in this domain, its recent rise on
the global agenda, and the concomitant
increase in resources devoted to combat-
ing it. Many old and new approaches have
evolved and been tested in the field of
malaria, including targeted programs like
WHO’s Malaria Action Programme and
the WHO/UNDP/Unicef/World Bank
Training in Tropical Diseases (TDR)
Programme; governance partnerships like
RBM; product development partnerships
Figure 2. Global Health as partnership. Today’s Roll Back Malaria Partnership consists of more than 500 partners, including the major players
WHO, the Global Fund, and the Bill & Melinda Gates Foundation. RBM was initiated in 1998 by WHO, UNICEF, UNDP, and the World Bank. WHO
currently hosts RBM’s secretariat and contributes in multiple ways. However, it is not presented as the central node of the partnership (source: http://
www.rollbackmalaria.org/).
doi:10.1371/journal.pmed.1000183.g002
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ture; and new delivery mechanisms such
as GFATM. Goals have oscillated between
global eradication, regional and national
control, and now perhaps back to global
eradication. Exploration of the evolution
of institutional arrangements linking ma-
laria research, development, and delivery
hold important lessons for understanding
the global health system more generally.
The fourth article of the series, by Moon
et al. [47], presents conclusions regarding
the threecentralquestionsraisedaboveand
poses questions for further research and
recommendations for future action.
Our hope is that this series stimulates
debate, encourages further case studies,
and provides insights into general princi-
ples for the improvement of the global
health system.
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